Related Experiment Video

Updated: Jul 6, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
15:05

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation

Published on: May 20, 2020

Epidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosis

Michael Vibo Grandal1, Inger Helene Madshus

  • 1University of Oslo, Institute of Pathology, Rikshospitalet, Oslo, Norway.

Journal of Cellular and Molecular Medicine
|March 6, 2008
PubMed

Insights

Epidermal growth factor receptor (EGFR) signaling drives cancer progression. Understanding EGFR activation and degradation is key to developing targeted cancer therapies.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Epidermal growth factor receptor (EGFR) and ErbB family members are critical regulators of cell proliferation, angiogenesis, migration, tumorigenesis, and metastasis.
  • Aberrant activation of ErbB proteins, driven by overexpression, mutations, deletions, or autocrine ligands, is implicated in various cancers.
  • EGFR signaling is complex due to homo- and heterodimerization with other ErbB proteins, influencing receptor stability and signaling output.

Purpose of the Study:

  • To review the mechanisms of ligand-induced EGFR activation.
  • To elucidate the processes involved in EGFR endocytic down-regulation.
  • To highlight the significance of EGFR biology in developing targeted cancer therapeutics.

Main Methods:

  • Review of preclinical and clinical data.
  • Analysis of signaling pathways regulating EGFR activation.
  • Investigation of receptor degradation mechanisms, focusing on lysosomal pathways.

Main Results:

  • EGFR is a central player in various cancers, including carcinomas, brain tumors, and non-small cell lung cancer.
  • Lysosomal degradation following ligand-induced endocytosis is the primary mechanism for EGFR down-regulation.
  • Association with ErbB2 can prevent EGFR down-regulation, emphasizing the role of cellular context.

Conclusions:

  • EGFR is a validated molecular target for cancer treatment.
  • A deeper understanding of EGFR biology, particularly its activation and down-regulation, is crucial for designing more tumor-selective therapies.
  • Targeting EGFR-induced signaling pathways holds promise for improved cancer treatment strategies.

More Related Videos

Automated Imaging and Analysis for the Quantification of Fluorescently Labeled Macropinosomes11:01

Automated Imaging and Analysis for the Quantification of Fluorescently Labeled Macropinosomes

Published on: August 24, 2021

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR activation may...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Amplifying Signals via Enzymatic Cascade01:22

Amplifying Signals via Enzymatic Cascade

When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...